Evidence map›Paper›PMID 40291708›Full record

ArticlebioRxiv : the preprint server for biology2025

Hypoimmunogenic hPSC-derived cardiac organoids for immune evasion and heart repair.

Sophia E Silver, Alessandro R Howells, Dimitrios C Arhontoulis, Lauren N Randolph, Nathaniel A Hyams, Ryan W Barrs, Mei Li, Charles M Kerr, Rob A Robino, Jordan E Morningstar and 9 more

Abstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in bioRxiv : the preprint server for biology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Sophia E SilverDepartment of Bioengineering, Clemson University, USA.ORCID 0000-0003-0718-591X
Alessandro R HowellsDepartment of Biomedical Engineering, The Pennsylvania State University, USA.ORCID 0000-0001-7741-340X
Dimitrios C ArhontoulisMolecular Cellular Biology and Pathobiology, Medical University of South Carolina, USA.ORCID 0000-0002-7959-7692
Lauren N RandolphDepartment of Biomedical Engineering, The Pennsylvania State University, USA.
Nathaniel A HyamsDepartment of Bioengineering, Clemson University, USA.ORCID 0009-0007-4158-3352
Ryan W BarrsDepartment of Bioengineering, Clemson University, USA.ORCID 0000-0001-7747-1941
Mei LiDepartment of Cardiology, Medical University of South Carolina, USA.
Charles M KerrMolecular Cellular Biology and Pathobiology, Medical University of South Carolina, USA.ORCID 0000-0001-8736-4795
Rob A RobinoDepartment of Pharmacology and Immunology, Medical University of South Carolina, USA.ORCID 0000-0002-1645-0247
Jordan E MorningstarDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, USA.ORCID 0000-0003-2168-9671
Jacelyn D BainDepartment of Bioengineering, Clemson University, USA.ORCID 0009-0009-5897-2711
Martha E FloyDepartment of Chemical and Biological Engineering, University of Madison-Wisconsin, USA.ORCID 0000-0003-1992-5911
Russell A NorrisDepartment of Regenerative Medicine and Cell Biology, Medical University of South Carolina, USA.ORCID 0000-0001-8462-5726
Xiaoping BaoDavidson School of Chemical Engineering, Purdue University, USA.ORCID 0000-0003-0955-6868
Jean Marie RuddyDepartment of Surgery, Medical University of South Carolina, USA.
Sean P PalecekDepartment of Chemical and Biological Engineering, University of Madison-Wisconsin, USA.ORCID 0000-0003-4917-5584
Leonardo M R FerreiraDepartment of Pharmacology and Immunology, Medical University of South Carolina, USA.ORCID 0000-0003-2491-9866
Xiaojun Lance LianDepartment of Biomedical Engineering, The Pennsylvania State University, USA.ORCID 0000-0002-9161-1004
Ying MeiDepartment of Bioengineering, Clemson University, USA.ORCID 0000-0002-8508-4076

Funding

Translational Science Laboratory Shared ResourceP30CA138313 · MEDICAL UNIVERSITY OF SOUTH CAROLINA · 2025 to 2025
$2.4M
Nanowired hypoimmunogenic hPSC cardiac organoids for heart repairR01HL175050 · CLEMSON UNIVERSITY · 2025 to 2025
$647k
Label-free single-cell imaging for quality control of cardiomyocyte biomanufacturingR01HL165726 · MORGRIDGE INSTITUTE FOR RESEARCH, INC. · 2025 to 2025
$631k
Silicon nanowire engineered human isogenic cardiac organoids for heart repairR01HL173532 · CLEMSON UNIVERSITY · 2025 to 2025
$581k
Nanowired humam cardiac organoid derived exosomes for heart repairR01HL168255 · CLEMSON UNIVERSITY · 2025 to 2025
$366k
NCI NIH HHS P30 CA138313NHLBI NIH HHS F30 HL160055NHLBI NIH HHS F31 HL154665NHLBI NIH HHS F31 HL156541NHLBI NIH HHS R01 HL133308NHLBI NIH HHS R01 HL165726NHLBI NIH HHS R01 HL168255NHLBI NIH HHS R01 HL173532NHLBI NIH HHS R01 HL175050NHLBI NIH HHS R21 HL167211NHLBI NIH HHS U01 HL169361NIBIB NIH HHS R21 EB026035NIDDK NIH HHS R56 DK133147NIGMS NIH HHS P30 GM103342
6 · The paper itself

Abstract

Human pluripotent stem cell (hPSC)-derived cardiac therapies hold great promise for heart regeneration but face major translational barriers due to allogeneic immune rejection. Here, we engineered hypoimmunogenic hPSCs using a two-step CRISPR-Cas9 strategy: (1) B2M knockout, eliminating HLA class I surface expression, and (2) knock-in of HLA-E or HLA-G trimer constructs in the AAVS1 safe harbor locus to confer robust immune evasion. Hypoimmunogenic hPSCs maintained pluripotency, efficiently differentiated into cardiac cell types that resisted both T and NK cell-mediated cytotoxicity

Identifiers

PMID40291708
PMCPMC12027337

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.